Search

Sponsor opportunities

EHA and the Lebanese Society of Hematology and Blood Transfusion (LSHBT) have initiated a webinar course dedicated to practitioners who manage patients with benign and hematologic malignancies with the practical tools to translate emerging data into the best therapy for…

Read more

EHA Issues Recommendations on Mild to Moderate Bleeding Disorders

HemaSphere presents first in a series of Consensus Reports on Diagnosis of Inherited Bleeding Problems

For hematologists, it can be challenging to make the correct diagnosis in patients with bleeding problems – or even to determine whether there is any bleeding…

Read more

Regulation on Health Technology Assessment

The Regulation on Health Technology Assessment (HTAR) was proposed by the European Commission in 2018. It was formally adopted in December 2021 and will apply from January 2025.

Read more

Lymphomas from A to Z

Nineteen countries from 3 continents were represented during the EHA-SWG Scientific Meeting on Rare Lymphomas on March 10-12, 2017 in Barcelona, Spain.

Read more

A European Reference Network for Rare Hematological Diseases

You may have heard of European Reference Networks (ERNs). But most likely you have not. ERNs are networks of specialized hospital departments and research centers to treat rare or low-prevalent complex diseases.

Read more

Meet Helen Papadaki, our January volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…

Read more

Meet Helen Papadaki, our January volunteer of the month

Can you tell us what you do for EHA and when you started?
I am currently a Councilor of the EHA Board for the period 2016-2020, chair of the EHA Membership Committee and vice-chair of the Scientific Working Group (SWG) on…

Read more

The Clot Thickens

Haemophilia B is a genetic bleeding disorder, affecting approximately 80,000 males worldwide1, caused by an insufficient or dyfunctional blood clotting protein called factor IX (FIX).

Read more